Antaros Medical is proud to have contributed to a phase 2a study in patients with elevated liver fat and body mass index (BMI), metabolic characteristics that may be indicative of metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH). The results of this study were recently published in The Lancet Gastroenterology & Hepatology.
Lars Johansson (CSO @ Antaros Medical) and Edvin Johansson (Senior Director MR Imaging @ Antaros Medical) were co-authors of the publication, contributing analysis of and insights drawn from the study’s imaging data.
The study, sponsored by Rivus Pharmaceuticals, involves assessment of several imaging-based measurements from baseline to after 61 days of treatment with one of three doses of a controlled metabolic accelerator (CMA) or placebo. Utilising non-invasive Magnetic Resonance Imaging (MRI) methods such as MRI proton density fat fraction (MRI-PDFF), changes in liver fat content, liver volume, and whole-body adiposity were assessed.
These imaging methods can be particularly useful for sensitively detecting and quantifying changes in smaller sample sizes with short treatment durations, as was the case in this study. You can read more about Antaros Medical’s whole liver assessment of liver fat content and volume here.
Title: Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
Authors: Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal A
Find the publication here.